Find Funding Opportunities

This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The goal of this FOA is to provide informatics support to NIH funded projects that are performing high-throughput broad based phenotyping of mouse knock-out (KO) lines (see RFA-RM-15-017) and to coordinate with international efforts so as to integrate all data into a common database under the auspices of the International Mouse Phenotyping Consortium (IMPC). The Data Coordination Center and Database (DCCDB) will perform the curation, analysis, visualization, and dissemination of the phenotype data from the knockout lines. Curation will require integration with other data sources. Analysis will require further development and validation of statistical methods.Visualization and queries will require innovative tools to disseminate the data in a real-time environment. The ultimate goals of these efforts are to enhance the ability of the biomedical research community to identify new disease models, to better understand phenotypic patterns, and to gain a more comprehensive understanding of the underlying function of each gene.

This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. The purpose of this FOA is to solicit applications for research projects to make maximum progress toward the goal of producing a null-mutant mouse phenotype resource for each gene in mouse strain C57BL/6, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The specific objectives of this FOA are to generate mutant mouse lines using CRISPR/Cas9 technology, perform phenotyping assays, conduct quality control assessments, cryopreserve germplasm, and make mice and data readily available to the research community. The mouse is the ideal mammalian system in which to produce a functional genomics resource because of the long history and depth of understanding of mouse genetics, the sophistication of assistive reproductive technology in the mouse system, short generation times, and the low cost of working with mice in comparison to other mammals. The recent breakthroughs in CRISPR/Cas9 technology make the mouse an even more cost effective model system and will drive technology of mouse production. The goal of this FOA is to support high-throughput broad based phenotyping of approximately 600 null-mutant mouse lines per year, with an overall goal of 3,000 lines for this five-year project period of the Knockout Mouse Phenotyping Program (KOMP2).

This Funding Opportunity Announcement (FOA) invites Cooperative Agreement (U10) applications for implementation of investigator-initiated randomized controlled clinical trials on alcohols effects on neurological diseases, most especially stroke, and the health issues that are associated with aging. Applicants for the U10 Clinical Trial Implementation Cooperative Agreement must be able to begin the trial without further planning activities when the U10 is awarded. Therefore, investigators who have already completed planning activities through an NIAAA-funded U34 clinical trial planning grant are expected to apply.

Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this FOA seeks applications to assemble integrated, multi-disciplinary teams to overcome these fundamental barriers. Projects should investigate high-impact questions in human neuroscience and disorders of the human nervous system. The research should be offered as experimental projects, or exploratory research and planning activities, for building teams, generating data and empirical results that will later compete for continued funding under new or ongoing FOAs of the BRAIN Initiative or under NIH Institute appropriations.

This Funding Opportunity Announcement (FOA) invites applications for Center Core Grants that provide resources and facilities shared by a minimum of six NINDS-supported investigators, and supporting a wider base of neuroscience research. The proposed Centers should offer services and expertise that would be difficult or impractical to support in individual labs. The Centers are expected to capitalize on economies and synergies associated with shared resources, and to foster a collaborative environment among neuroscientists at host institutions.

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, this FOA specifically seeks to support efforts that will revolutionize our understanding of the biological activity underlying, and bioinformatic content of, data collected using contemporary non-invasive functional brain imaging techniques. The hope is that these transformative discoveries will lead to breakthroughs in understanding the dynamic activity of the human brain.

The purpose of this FOA is to solicit applications for an Epilepsy Center without Walls (CWOW) focused on collaborative preclinical and clinical research to prepare for translational and clinical development of disease modifying or prevention therapies for epilepsy. An additional goal is to develop community partnerships and community resources to advance development of such therapies.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for projects to transfer technology out of the NIH intramural research labs into the private sector. If selected for SBIR funding, the SBC will be granted a royalty-free, non-exclusive patent license agreement for internal research use for the term of and within the field of use of the SBIR award to technologies held by NIH with the intent that the SBC will develop the invention into a commercial product to benefit the public.

The purpose of the NINDS Child Neurologist Career Development Program (CNCDP) is to facilitate and support the research career development of child neurologists, at educational institutions or professional organizations, who have made a commitment to independent research careers.The CNCDP is a single national program, implemented by either a single PD/PI or multiple co- directors (at least one of whom is the PD/PI), together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of clinician scientists. The CNCDP will generally provide three consecutive years of support to individuals to provide them with the knowledge, tools and research experience that will enable them to develop a significant research project funded by an individual career development award or research grant.

This FOA is intended to facilitate partnerships between clinical investigators and manufacturers of latest-generation stimulating and/or recording devices that are FDA-designated as Class III (invasive, posing significant risk of harm), to conduct clinical research in the central nervous system.As part of The BRAIN InitiativeSM, NIH has initiated a Public-Private Partnership program (BRAIN PPP) to reduce barriers to negotiating such partnerships, and to ensure that new clinical studies leverage manufacturers existing data demonstrating safety and utility of these devices.Safety and utility data for invasive devices are costly to obtain, yet they are necessary for regulatory approval of human research, and therefore pose a substantial barrier to research progress.For this program, NIH has entered into agreements with a number of manufacturers to make available next generation devices that can stimulate and/or record from the central nervous system and have sufficient data to enable new Non-Significant Risk (NSR) or Investigational Device Exemption (IDE) without the need for significant additional testing.